HH&L Acquisition Corp. (HHLA) to Combine with DiaCarta in $460M Deal

Oct 14, 2022 Deal Announcements & Amendments, Headline Post, INTEL by Nicholas Alan Clayton

HH&L (NYSE:HHLA) has entered into a definitive agreement to combine with biotech firm DiaCarta at a pre-money equity value of $460 million. Pleasanton, California-based DiaCarta produces a range of viral and DNA tests to detect ailments early or perform tasks in conjunction with treatment. The combined company is expected to trade on the NYSE once
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

HH&L Acquisition Corp. (HHLA) to Combine with DiaCarta in $460M Deal

HH&L Acquisition Corp. (HHLA) to Combine with DiaCarta in $460M Deal

ByNicholas Alan Clayton